Zhe Yuan1, Vincent H Tam. 1. Chongqing Medical University, The First Affiliated Hospital, Department of Infectious Diseases, Chongqing 400016, China.
Abstract
BACKGROUND: There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent. OBJECTIVE: To review what is known about polymyxin B and to identify missing information or gaps for future investigations. METHODS: Pertinent information was reviewed from published literature in English. RESULTS/ CONCLUSION: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.
BACKGROUND: There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent. OBJECTIVE: To review what is known about polymyxin B and to identify missing information or gaps for future investigations. METHODS: Pertinent information was reviewed from published literature in English. RESULTS/ CONCLUSION: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.
Authors: Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam Journal: Int J Antimicrob Agents Date: 2013-08-22 Impact factor: 5.283
Authors: Kamilia Abdelraouf; Kirk H Braggs; Taijun Yin; Luan D Truong; Ming Hu; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2012-06-11 Impact factor: 5.191
Authors: Kamilia Abdelraouf; Jie He; Kimberly R Ledesma; Ming Hu; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2012-08-20 Impact factor: 5.191
Authors: Pooja Manchandani; Jian Zhou; Kimberly R Ledesma; Luan D Truong; Diana S-L Chow; Jason L Eriksen; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191